Literature DB >> 15336974

Calstabin deficiency, ryanodine receptors, and sudden cardiac death.

Stephan E Lehnart1, Xander H T Wehrens, Andrew R Marks.   

Abstract

Altered cardiac ryanodine receptor (RyR2) function has an important role in heart failure and genetic forms of arrhythmias. RyR2 constitutes the major intracellular Ca2+ release channel in the cardiac sarcoplasmic reticulum (SR). The peptidyl-prolyl isomerase calstabin2 (FKBP12.6) is a component of the RyR2 macromolecular signaling complex. Calstabin2 binding to RyR2 is regulated by PKA phosphorylation of Ser2809 in RyR2. PKA phosphorylation of RyR2 decreases the binding affinity for calstabin2 and increases RyR2 open probability and sensitivity to Ca2+-dependent activation. In heart failure, a majority of studies have found that RyR2 becomes chronically PKA hyper-phosphorylated which depletes calstabin2 from the channel complex. Calstabin2 dissociation causes a diastolic SR Ca2+ leak contributing to depressed intracellular Ca2+ cycling and decreased cardiac contractility. Missense mutations linked to genetic forms of exercise-induced arrhythmias and sudden cardiac death also cause decreased calstabin2-binding affinity and leaky RyR2 channels. We review the importance of calstabin2 for RyR2 function and excitation-contraction coupling, and discuss new observations that implicate dysregulation of calstabin2 binding as a central mechanism for abnormal calcium cycling in heart failure and triggered arrhythmias. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15336974     DOI: 10.1016/j.bbrc.2004.08.032

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

1.  Gain of function of cardiac ryanodine receptor in a rat model of type 1 diabetes.

Authors:  Chengju Tian; Chun Hong Shao; Caronda J Moore; Shelby Kutty; Timothy Walseth; Cyrus DeSouza; Keshore R Bidasee
Journal:  Cardiovasc Res       Date:  2011-03-18       Impact factor: 10.787

Review 2.  Altered intracellular Ca2+ handling in heart failure.

Authors:  Masafumi Yano; Yasuhiro Ikeda; Masunori Matsuzaki
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

Review 3.  Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca2+ release channels.

Authors:  Silvia G Priori; Carlo Napolitano
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

4.  Illicit organogenesis: Methods and substances of doping and manipulation.

Authors:  Mario Thevis; Wilhelm Schänzer
Journal:  Organogenesis       Date:  2008-10       Impact factor: 2.500

Review 5.  Calsequestrin mutations and catecholaminergic polymorphic ventricular tachycardia.

Authors:  Michela Faggioni; Dmytro O Kryshtal; Björn C Knollmann
Journal:  Pediatr Cardiol       Date:  2012-03-16       Impact factor: 1.655

6.  Accelerated sinus rhythm prevents catecholaminergic polymorphic ventricular tachycardia in mice and in patients.

Authors:  Michela Faggioni; Hyun Seok Hwang; Christian van der Werf; Ineke Nederend; Prince J Kannankeril; Arthur A M Wilde; Björn C Knollmann
Journal:  Circ Res       Date:  2013-01-07       Impact factor: 17.367

Review 7.  The ryanodine receptor in cardiac physiology and disease.

Authors:  Alexander Kushnir; Andrew R Marks
Journal:  Adv Pharmacol       Date:  2010

Review 8.  Cardiac adrenergic control and atrial fibrillation.

Authors:  Antony J Workman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-04       Impact factor: 3.000

9.  Ryanodine receptor allosteric coupling and the dynamics of calcium sparks.

Authors:  Jeffrey R Groff; Gregory D Smith
Journal:  Biophys J       Date:  2008-03-21       Impact factor: 4.033

10.  Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects.

Authors:  X-H Zhang; S Haviland; H Wei; T Sarić; A Fatima; J Hescheler; L Cleemann; M Morad
Journal:  Cell Calcium       Date:  2013-05-17       Impact factor: 6.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.